ViroPharma and Wyeth-Ayerst Initiate Human Clinical Trials for Hepatitis C Treatment

Strategic Insights -

ViroPharma Inc. and American Home Products Corp.'s Wyeth-Ayerst Laboratories have initiated human clinical trials for a compound to treat hepatitis C. The trials, conducted at a medical facility in the United Kingdom, aim to evaluate the safety of the compound in healthy human volunteers. This development is a significant step in addressing the global burden of hepatitis C, which is responsible for an estimated 170 million infections worldwide and causes around 8,000 to 10,000 deaths annually in the United States alone.

Key Takeaways:

  • ViroPharma and Wyeth-Ayerst Laboratories are collaborating to develop a compound for the treatment of hepatitis C, which has shown efficacy in inhibiting the replication activity of the virus in laboratory studies.
  • The compound is the first member of a group of small molecule compounds being developed under the collaboration, with the goal of determining its potential clinical benefit in human clinical trials.
  • Hepatitis C virus is a major cause of chronic hepatitis worldwide, affecting approximately 170 million people globally, and responsible for around 8,000 to 10,000 deaths in the United States annually.
  • Current treatments for hepatitis C are effective in only 10-40% of patients, highlighting the need for new therapeutic options.
  • The clinical trials will be conducted at a medical facility in the United Kingdom, with the primary goal of evaluating the safety of the compound in healthy human volunteers.

Statistics:

  • Approximately 170 million people are infected with hepatitis C worldwide.
  • The World Health Organization estimates that an additional 9 million individuals are infected with HCV in Europe.
  • Nearly four million people are infected with HCV in the United States.
  • Hepatitis C is responsible for an estimated 8,000 to 10,000 deaths in the United States annually.
  • Current treatments for hepatitis C are effective in only 10-40% of patients.

Sources:

  • NewsRx.com
  • ViroPharma Inc.
  • American Home Products Corp.
  • Wyeth-Ayerst Laboratories
  • U.S. Centers for Disease Control and Prevention (CDC)
  • World Health Organization
  • Hepatitis Weekly